Skip to main content
SpringerLink
Log in

Acceptable VTE risk with ethinylestradiol/drospirenone

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Venous thromboembolism

  2. International Active Surveillance Study of Women Taking Oral Contraceptives

References

  1. Dinger J, et al. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception 89: 253-263, 4 Feb 2014. Available from: URL: http://dx.doi.org/10.1016/j.contraception.2014.01.023

  2. Reid RL. Oral hormonal contraception and venous thromboembolism (VTE). Contraception 89: 235-236, 14 Apr 2014. Available from: URL: http://dx.doi.org/10.1016/j.contraception.2014.02.002

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Acceptable VTE risk with ethinylestradiol/drospirenone. Reactions Weekly 1498, 2 (2014). https://doi.org/10.1007/s40278-014-0332-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-0332-9

Search

Navigation